Despite beating on its earnings Thursday, pharma giant Eli Lilly (LLY) suffered a nearly 12% loss in its stock, losing more than $90 billion in market cap in a single day. "We think the market ...

Eli Lilly (LLY) reported first quarter earnings on Thursday, beating Wall Street's expectations on the top and bottom lines, but its stock sank more than 11% in trading despite the win. The ...

Here’s an idea for the next episode of “The Eli Manning Show.” The former quarterback visits various investors and tries to pool enough money to buy a minority ownership stake in the Giants.

Positive results for Eli Lilly's new diabetes and weight-loss drug have recently boosted its stock price. Data from several studies on the GLP-1 drug are expected to come out this year.

Michael Nagle / Bloomberg via Getty Images Shares of Eli Lilly (LLY) fell sharply Thursday morning after the pharmaceutical giant's lowered profit projections outweighed first-quarter results that ...

Eli Lilly & Co. said Tuesday it’s cutting the price of single-dose vials of its Zepbound treatment for diabetes and obesity for patients who have to pay for the drug themselves. It said it will ...

Eli Manning has his sights on the Giants. The two-time Super Bowl winning quarterback is putting together an ownership group to bid for a piece of the Giants, according to Bloomberg. The report ...

Eli Lilly & Co.’s stock soared 14% Thursday, to put it on track for its biggest one-day gain in about 25 years, after the drugmaker reported positive results from a late-stage trial of a GLP-1 ...

Eli Lilly (LLY) has enjoyed a successful run the past several quarters as the company's blockbuster GLP-1 weight-loss drug Wegovy gains steam in the obesity space. Wegovy was first to market but ...

Looking ahead, Eli Lilly narrowed its full-year guidance. It now expects fiscal 2025 EPS in the range of $20.78 to $22.28, falling short of the $22.40 analysts had penciled in. Revenue is ...

The last couple of quarters have been very favorable for Eli Lilly and Company (NYSE:LLY) and its position in the obesity and adjacent markets. The main competitor Novo Nordisk A/S (NVO ...

Global pharmaceutical company Eli Lilly (NYSE:LLY) reported Q1 CY2025 results exceeding the market’s revenue expectations , with sales up 45.2% year on year to $12.73 billion. The company ...